lunes, 15 de enero de 2024

Wondering why you’ve never heard about LDN?

 Wondering why you’ve never heard about LDN, an amazing and inexpensive drug used to alleviate conditions from chronic pain to autoimmunity to weight management?  


Well, you probably haven't heard of low dose naltrexone (LDN) because there’s no billion-dollar pharma conglomerate willing to fork out the big bucks needed to do a large-scale study on LDN.  As a humble drug with an expired patent, and despite over 90 published studies on the various benefits of LDN, from pain management, fibromyalgia, auto-immunity, Crohn's disease, multiple sclerosis, weight management and even cancer, naltrexone has never been picked up by a pharma company willing to pay out the enormous FDA approval costs for a medication they cannot sell exclusively.  So, if no one else has introduced you, we would like you to meet the little engine that could: Low Dose Naltrexone.


Low Dose Naltrexone (LDN) has emerged has an inexpensive and effective treatment for many chronic health conditions including excess weight.  Naltrexone, originally used to help manage opioid use disorders by preventing the euphoria (“high”) caused by opiates, is now recognized as a complimentary treatment for many chronic conditions.  Naltrexone, when used in very low doses, has been found to safely treat a host of conditions and symptoms with minimal side effects.



What is naltrexone?


Naltrexone is a drug that has been used to help people recover from opiate and alcohol use disorders.  However, off-label use of Naltrexone, in much lower doses, has shown benefit in a variety of conditions because of the way naltrexone temporarily binds to opioid receptors in the brain. Binding these receptors promotes the compensatory production of natural endorphins which then have the ability to affect the body’s immune system and slow the production of cells that can negatively influence various medical conditions. 


Low Dose Naltrexone (LDN), in addition to other disease modifying therapeutic modalities, has demonstrated an ability to alleviate a wide variety of medical conditions and symptoms, like:


Fibromyalgia

Ulcerative colitis and Crohn’s Disease

Multiple sclerosis

Rheumatoid arthritis

Chronic pain caused by many conditions

Hashimoto’s thyroiditis

Epstein Barr virus/ Chronic Fatigue Syndrome

Pernicious anemia

Lupus and other auto-immune conditions

Scleroderma

Excess Weight

PCOS

Growing evidence has demonstrated that our natural endorphins, most commonly known as our natural, pain-killers, also play an important role in immune system regulation among other functions. LDN has been associated with symptom improvement in conditions such as fibromyalgia, Ulcerative Colitis/Crohn’s disease, rheumatoid arthritis, multiple sclerosis, lupus and other auto-immune syndromes, depression, Hashimoto’s Thyroid Disease, complex regional pain syndrome, excess weight and more.


 


LDN has been found to aid chronic pain by temporarily binding and blocking a mechanism called the MU receptor, which is linked to pain. Blocking the receptor tells our bodies that we aren’t producing enough endorphins (our natural pain relievers), and then releases them.


 


How does LDN work?


LDN works as an opioid antagonist. LDN can boost the body’s endorphins and enkephalins. In low doses, LDN promotes the release of endorphins over an extended period of time.  This rise in endorphins contributes reduced inflammation and upregulated immune function, and endorphin rise has been attributed to a decrease in symptoms and progression of chronic disease.  


The LDN Trust explains explains LDN’s mechanism of actions occur as Levo and Dextro naltrexone antagonize the opiate/endorphin receptors causing the following:


Increase endorphin release by temporarily binding to the MU receptors

Endorphins modulate the immune response

Modulation of the immune system reduces the speed at which unwanted cells grow

Antagonizes TLR: suppressing cytokine modulated immune system

Antagonizes TLR-mediated production of NF-kB: reducing inflammation, potentially down regulating oncogenes

LDN can also help suppress microglial activity.  Microglia immune cells are the primary immune cells in our central nervous system. They are responsible for inflammatory response due to exposure to pathogens or from injury.  When microglia are activated, they secrete pro-inflammatory cytokines, prostaglandins, nitric oxide and excitatory amino acids. 

 

How Will LDN Make Me Feel?

Because LDN can increase endorphins, you may feel an overall sense of well-being. Human trials have demonstrated improvement in self-reported depression, wellness and quality of life scores. Feeling well helps lower stress, reduces depression, and increases healing.  Feeling well may also affect over eating and lead to improved weight management.


LDN is typically prescribed at bedtime as the majority of endorphin production in our body occurs while sleeping. Some individuals may experience sleep changes with bed-time dosing and if this occurs, taking LDN during waking hours may be preferable.


Naltrexone, when used in very low doses, has been found to safely treat a host of conditions and symptoms with minimal side effects


 

What About Side effects?

Side effects of LDN are often minimal and usually transient which makes this medication an easy addition for most patients. Naltrexone may cause the following side effects at maximal doses, however, with low dose regiments these side effects are typically minimal and transient:


nausea and vomiting

abdominal pain

constipation

decreased appetite

headache

fatigue

insomnia

dizziness

depression

anxiety

 


Who Should NOT Take LDN?

You shouldn’t take LDN if you:

currently take prescribed opioid medications or street drugs

are in an opioid maintenance program and/or are taking suboxone or methadone

are in acute opiate or alcohol withdrawal

have liver problems or abnormal liver tests

if you are currently being treated for or have an alcohol use disorder

you should discontinue LDN before surgery or if you plan to take prescribed opioid medications

you should not take LDN if you are pregnant, plan to become pregnant or are breastfeeding

 

Remember, LDN is not a treatment for acute conditions.  LDN is for the treatment of chronic disease and, despite over 90 studies published on the various uses of LDN, from pain relief, fibromyalgia, Crohn's disease, multiple sclerosis, systemic sclerosis and even cancer, LDN therapy is considered off-label use and is not FDA approved for use outside of opiate and alcohol use disorder. It’s very important to talk to your healthcare provider before trying LDN to ensure it won’t interact with any other medications you may be taking and you should not stop any of your treatment medications before consulting with your specialist.


 How is LDN dosed and monitored?


The most common LDN dosages are 1.5mg, 3mg, and 4.5mg taken at bedtime. LDN may be titrated up or down based on how a person responds to treatment. If a patient is sensitive to medications, providers will often start at an ultra-low dose of just 0.5mg per day and then titrate up gradually to a maximum dose of 4.5mg.  For the treatment of excess weight, doses may be split morning and evening and may be recommended at a slightly higher dosing.


The goal with LDN, as with many medications, is to take the lowest therapeutic dose rather than the highest dose that can be tolerated. LDN is a unique medication and must be individualized.  The right dose for one individual may be 1mg and for another 4.5mg even when both individuals are being treated for the same chronic condition.


Never try to break, alter or manipulate naltrexone tablets to create LDN on your own.  You should always consult a healthcare professional to help you determine which approach is best for your condition and decide on the best LDN dosage to help you combat symptoms.


LDN therapy is just one part of a treatment plan that also includes a balanced lifestyle, good nutrition or auto-immune paleo diet, exercise, and possibly other medications to achieve optimal response.  Regular check-ins with your provider are recommended both to assess your progress and manage dose titration.  You should have an in-person check up at least several times per year while on LDN therapy.


 

How Thrive Wellness Can Help

LDN is a promising pharmacologic approach for the treatment of chronic diseases and excess weight, and ongoing research supports its use. Since LDN is effective, inexpensive and has few side effects, it is likely that LDN will eventually be regarded as one of the most promising complimentary treatments for many chronic diseases.


At Thrive Wellness, we work closely with our compounding pharmacy partners to ascertain the best dosing strategy for each patient’s particular condition and needs. Response to treatment varies in terms of time and dosing but over treatment course, many have found relief from pain, weight management success and other improvement of long-standing chronic symptoms.


If you think LDN therapy might be right for you, reach out to a Thrive Team Member to schedule a consultation to explore how LDN might benefit your and support your health journey.


How Can LDN Help with Weight Management?


Ways LDN Has Been Found to Aid in Weight Management:

Reduces Insulin Resistance


Curbs Appetite and Reduces Cravings


Can Boost Growth Hormones


Anti-inflammatory Effects


Promotes Better Sleep


Improves Thyroid Function


 Although we don’t entirely understand LDN’s mechanism for weight loss, studies have suggested that it may help curb appetite by reducing the appeal of food.  This effect results in a reduction of food cravings.  In addition, LDN may also contribute to a rise in growth hormone levels which can help build lean muscle and burn fat.  In patients with insulin resistance, which contributes to weight gain, belly fat, diabetes, heart disease and other conditions, LDN can improve insulin sensitivity and eventually lower insulin levels making it easier for cells to utilize insulin.

LDN in Combination with Other Medications

LDN with GLP-1 Agonists

LDN combined with a GLP-1 agonist like Saxenda or Wegovy https://www.restartmed.com/victoza-weight-loss/ can be beneficial in patients with severe insulin and/or leptin deficiency or resistance. For more information about GLP-1 agonists, read our blog post about GLP-1s for weight management.


How LDN Addresses Weight Loss Resistance

Insulin Resistance and PCOS

In the study Naltrexone effects on insulin sensitivity and insulin secretion in hyperandrogenic women, women using up to 75mg of naltrexone were found to have improved fasting insulin levels which decreased by 40%.  Insulin resistance is related to weight gain and weight loss resistance.  Higher levels of insulin are also associated with an increase in testosterone levels which are commonly found in women with PCOS.  Therefore, addressing insulin resistance is an important factor in the management of PCOS.  Naltrexone’s apparent influence on insulin resistance can explain it’s benefit in weight loss and indirect improvement of PCOS symptoms by the effect of lowering both insulin and testosterone.


Growth Hormone

In the study Influence of chronic Naltrexone treatment on growth hormone and insulin secretion in obese subjects showed that naltrexone exerts an effect that decreases insulin and increases human growth hormone.  GH helps us develop lean muscle mass and improves fat burning capacity which together can lead to weight loss.  It is postulated that as insulin increases, growth hormone decreases.  Naltrexone can help break the cycle of elevated insulin, weight gain and decreased growth hormone by shifting the balance to lower insulin, weight loss and increased growth hormone leading to the ability to develop more lean muscle mass and better calorie burning capabilities.


Inflammation is involved in the pathophysiology of many disease states.  Inflammation is also a big factor that influences weight gain and weight loss resistance.


Anti-Inflammatory Effects and Thyroid Function


LDN is well known for its beneficial effect on thyroid function especially in treating Hashimoto’s thyroiditis. Naltrexone is also well known for exerting anti-inflammatory effects on the body.  In the paper The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain, the authors proposed that LDN demonstrated reduced symptom severity in conditions like fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome. The author’s reviewed the evidence that LDN may operate as a novel anti-inflammatory agent in the central nervous system, via action on microglial cells.  When microglia are activated, they secrete pro-inflammatory cytokines, prostaglandins, nitric oxide and excitatory amino acids. Reducing the activity of microglial cells consequently reduces inflammatory response.  Inflammation is involved in the pathophysiology of many disease states.  Inflammation is also a big factor that influences weight gain and weight loss resistance. 


Inflammation may lead to:

thyroid resistance: reduced conversion of T4 to T3

Increased insulin resistance, weight gain and weight loss resistance

Increased leptin levels leading to weight gain

Increased appetite

By relieving inflammatory cytokines and markers of inflammation hormone levels become more regulated and balanced which may allow easier weight loss.  Research studies suggest that the use of LDN can help to improve the immune system function and reduce autoantibodies in some autoimmune conditions like Hashimoto’s thyroid disease.  In some studies LDN has been found to increase thyroid hormone levels while reducing thyroid auto-antibodies associated with Hashimoto’s thyroid disease.


Hashimoto’s Thyroid Disease is an autoimmune disease that leads to thyroid gland destruction over time ultimately resulting in hypothyroidism and weight gain or weight loss resistance.


Sleep

The importance of sleep and its influence on weight loss is huge.  Poor sleep leads to rising inflammation, metabolic issues, hypertension and weight gain which ultimately causes or worsens sleep apnea.


Naltrexone is associated with improved sleep in the majority of patients.  Improving sleep leads to improvements in metabolism, insulin resistance, inflammation and reduced pain.  This is why it is preferred that patients take LDN at bedtime. Some investigators suggest that LDN may be improving sleep through the modulation of neurotransmitter levels or via melatonin precursors. 


We still have a lot to understand about the use of LDN and its effects on weight management especially considering the multiple mechanisms of action as discussed.  Nonetheless, LDN shows amazing promise as a safe, affordable and effective tool in achieving a healthy weight and promoting a state of overall wellness.


Since LDN is effective, inexpensive and has few side effects, it is likely that LDN will eventually be regarded as one of the most promising complimentary treatments for many chronic diseases


How Does Naltrexone Help With Weight Loss?

While higher doses of Naltrexone are used to treat drug addiction, you can use lower doses to help with weight loss. The same way that the drug manages a person’s addiction is the same way that the drug can help a person manage their eating habits. Naltrexone helps with weight loss in the following ways:


Managing appetite: When the body functions normally, it signals your appetite to prompt hunger to ensure you get the right calories each day. For some people, this signal may continue even after someone has eaten enough calories for the day, causing them to gain weight. A person’s appetite may also slow or hormonal issues can cause a person’s body to signal a need for more calories than necessary. Naltrexone can help bring back balance to the body, allowing a person’s appetite to function correctly. The medication can help individuals consume less than they would without it.

Reducing inflammation: Inflammation can cause numerous issues that contribute to weight fluctuations, such as thyroid issues, diabetes, hormone levels and more. Individuals already struggling with their weight can experience additional challenges due to inflammation. Low doses of Naltrexone can help with inflammation and pain, which could resolve some issues that cause weight gain. 

Improving sleep: Poor sleep can create issues with weight gain since it can cause inflammation, which we’ve discussed above how it can contribute to weight gain. Sleep trouble and weight gain can become a vicious cycle, contributing to numerous health issues. Naltrexone can help with insomnia and other sleep issues that contribute to a person’s weight gain.

Increasing growth hormones: There are growth hormones that the body produces in the pituitary gland, which is responsible for controlling fat, maintaining bone density, building muscle and managing cholesterol. When a person gains weight or has hormonal imbalances, it affects their growth hormone, which can cause a person’s fat levels to increase along with other issues. Naltrexone can potentially increase the growth hormone in a person’s pituitary gland, helping them lose weight.

Assisting with thyroid issues: Inflammation caused by thyroid issues can contribute to weight fluctuations. Naltrexone can help reduce inflammation, allowing people to lose weight and improve their overall health.

Lowering insulin resistance: Insulin resistance can also contribute to weight gain. Naltrexone can help people with insulin resistance caused by hyperinsulinemia, helping them lose weight while restoring healthy insulin levels.


According to the Journal of American Family Physicians, Contrave (Naltrexone/Bupropion) is effective at helping people lose weight and sustain their weight loss. In all the studies cited in the journal, Naltrexone combined with dieting and an exercise routine contributed to significant weight loss compared to a placebo. 


It’s essential to note that while Naltrexone works to help individuals lose weight, it works best when paired with a diet and exercise routine. Behavioral and lifestyle changes can help a person lose weight and reach their goals sooner than if they were taking the medication independently. A person should always talk with their doctor before starting new medications and disclose their medical history, including conditions they have or had in the past.


How Long Should You Take Naltrexone to Lose Weight?

The amount of time you take Naltrexone will depend on your weight loss goals. A medical professional will give you a prescription for a low dose of the medication in a pill or as a pellet implanted under the skin. Before you start taking the drug, a medical professional will take you through an assessment to ensure that you’re a good candidate for the medication.


During your time taking the medication, a medical professional will monitor different factors, such as:


Body fat percentage

Obesity

Extracellular water weight

Visceral body fat

Metabolic rate

Skeletal muscle mass

Segmental fat

As you progress through your weight loss journey, your doctor will mark down the above information to see how close you are to achieving your goals. You will likely also take supplements alongside Naltrexone to help you sustain healthy nutrient levels and help you progress sooner through your weight loss journey. 


If you’re considering using weight loss medication and supplements to help you reach your goals, Synergy Wellness is here to help. We have various medications and supplements to help you lose weight, including Naltrexone, Phentermine, vitamin B12, CMWL multivitamins and trimolin. Our specialists will work with you to determine which combination of medications or supplements would best suit your individual needs and help you reach your goals.


Finding the right balance of medications and supplements is essential to ensure your health while maintaining your ideal weight. As you go through your weight loss journey, we’ll monitor how you’re doing on the current regimen and determine if we need to make any changes. If you’re ready to start your weight loss journey, contact Synergy Wellness to learn more about how we can help.

 

https://www.thrivewellnessla.com/blog/low-dose-naltrexone-best-kept-secret-in-treating-chronic-disease-and-excess-weight


--------------------------------------


1997 Nov;21(11):1076-81. doi: 10.1038/sj.ijo.0800519.

Influence of chronic Naltrexone treatment on growth hormone and insulin secretion in obese subjects

L De Marinis 1, A Mancini, D Valle, A Bianchi, A M De Luca, A M Fulghesu, P Villa, S Mancuso, A Lanzone

Affiliations expand

PMID: 9368834 DOI: 10.1038/sj.ijo.0800519

Cite

Abstract

Objective: Recent studies have demonstrated the restoration of a normal 24 h GH profile induced by a reduction of insulinaemia after weight loss, suggesting a reciprocal relationship between plasma insulin and GH concentrations. We aimed to clarify if an opiate-induced reduction in plasma insulin could affect GH secretion in obesity.


Design: We have studied the insulin response to an oral glucose tolerance test (OGTT) and the GH response to GHRH before and after prolonged treatment with Naltrexone (NTX). C-peptide, IGF-I, IGFBP-3 plasma levels and the IGF-I/IGFBP-3 molar ratio were also determined.


Subjects: Twelve obese women (aged 25-41 y; Body mass index (BMI): 31-39 kg/m2) and six lean normal women (aged 25-38; BMI: 19.8-23.1 kg/m2).


Measurement: GH was determined by the IRMA method; insulin, C-peptide, IGF-I and IGFBP-3 were assayed by the RIA method. For molar comparison between IGF-I and IGFBP-3 we have considered 30.5 kDa the molar weight of IGFBP-3. Results are expressed as mean +/- s.e.m.


Results: We observed a significant decrease in basal concentration of both insulin (230.1 +/- 34.9 vs 133.2 +/- 16.9 pmol/L; P < 0.005) and C-peptide (3.7 +/- 0.3 vs 2.4 +/- 0.1 micrograms/L; P < 0.02). No modifications in the insulin secretory response to the OGTT were observed. A significant increase of the GHRH-induced GH peak response (7.7 +/- 1.4 vs 19.7 +/- 3.1 micrograms/L; P < 0.01) and GH-AUC (533 +/- 151 vs 1415 +/- 339 micrograms/L/120 min; P < 0.01) was found after NTX treatment. A negative correlation was found between basal insulin and GH peak values, both before (r = -0.641, P = 0.027) and after NTX (r = -0.714, P = 0.013). No modifications were found in IGF-I, IGFBP-3 and IGF-I/IGFBP-3 molar ratio. Moreover, NTX affected neither the insulin response to OGTT or IGF-I, IGFBP-3 and IGF-I/IGFBP-3 molar ratio in a group of six lean controls. Conversely, NTX significantly reduced the GH response to GHRH, when expressed as both peak and AUC values.


Conclusions: The opiate antagonist significantly reduced basal insulin concentrations and augmented the GH response to GHRH in obese subjects. In the absence of modifications in IGF-I and IGFBP-3 plasma levels and their molar ratio, we propose that insulin may exert a negative feedback on GH secretion.


 

miércoles, 23 de agosto de 2023

Heroin and naltrexone effects on pituitary-gonadal hormones in man: interaction of steroid feedback effects, tolerance and supersensitivity.

 J H Mendelson, J Ellingboe, J C Kuehnle and N K Mello. Journal of Pharmacology and Experimental Therapeutics September 1980,

Abstract

The acute and chronic effects of heroin, and the opiate antagonist naltrexone, on integrated plasma samples analyzed for luteinizing hormone (LH) and testosterone (T) levels were studied in six adult males with a history of heroin addiction. Acute doses of heroin (10 mg i.v.) significantly suppressed LH levels. Chronic heroin use was also associated with a significant decrease in plasma T levels. LH levels after chronic heroin use were lower than control levels but the degree of LH suppression was approximately the same as after the acute doses of heroin. Acute naltrexone administration did not alter T levels appreciably but was associated with a significant elevation in LH levels. After 22 days of chronic naltrexone maintenance, T levels were in the high normal range and LH levels were in the low normal range. These data suggest the development of tolerance and supersensitivity to opiate agonist and antagonist effects on pituitary-gonadal hormones involves interaction between the direct effects of these drugs on LH followed by steroid feedback effects of T on gonadotrophin secretory activity.

Antitumor activity of naltrexone and correlation with steroid hormone receptors

 Abstract

We have evaluated the opiate peptide antagonist, naltrexone, for its effectiveness as an antitumor agent. For this evaluation, we tested the effect of naltrexone given daily in the diet on the growth of established 7,12-dimethylbenz(a)anthracene-induced mammary tumors. Tumors continued to grow actively in rats fed chow diet only (control group). In contrast, the naltrexone-supplemented diet (75 mg/kg diet) significantly decreased the size of the established mammary tumors in rats over the 25 day observation period, resulting in an average decrease in tumor volume by approximately 23% compared with their sizes at the beginning of the treatment. Tumor regression occurred in 70% of the rats. Tumors that respond to naltrexone showed appreciable amounts of estrogen and progesterone receptors while unresponsive tumors were negative for estrogen and progesterone receptors. For the first time, we report that naltrexone can regress established mammary tumors and that the inhibitory effect of naltrexone appears to be restricted to the hormonally responsive mammary tumors.

lunes, 7 de agosto de 2023

Influence of low dose naltrexone on Raman assisted bone quality, skeletal advanced glycation end-products and nano-mechanical properties in type 2 diabetic mice bone

 © 2021 - Abstract

Type 2 diabetes mellitus (T2DM) commonly affects the bone mineral phase and advanced glycation end-products (AGEs) which eventually led to changes in bone material properties on the nano and macro-scale. Several anti-diabetic compounds are widely used to control high blood sugar or glucose caused by T2DM. 

Low Dose Naltrexone (LDN), an opiate receptor antagonist, and a known TLR4 antagonist, treatment can improve glucose tolerance and insulin sensitivity in high-fat-diet (HFD) induced T2DM mice. However, the influences of LDN on the local bone quality, mineralization of the bone, and the skeletal AGEs levels have not been fully elucidated. The objective of this study is to understand the effect of LDN on Raman assisted bone quality, skeletal AGEs (determined by Raman spectroscopy), and nano-mechanical properties in HFD induced T2DM mice bone. In order to investigate these, mice and corresponding bones were divided into four groups (divided based on diet and treatment), (a) normal control diet treated with saline water, (b) normal control diet treated with LDN, (c) HFD treated with saline water, and (d) HFD treated with LDN. In T2DM condition (HFD treated with saline water), alteration of Raman-based compositional measures in bone quality including mineral-to-matrix ratios, carbonate substitution, mineral crystallinity, and collagen quality was observed. Our data also indicated that T2DM enhances the skeletal AGEs, and impairs the nano-mechanical properties. 

Interestingly, present results indicated that LDN controls the Raman-based compositional measures in bone quality in HFD induced T2DM mice bone. Additionally, LDN also protects the alteration of the skeletal AGEs levels and nano-mechanical properties in T2DM mice bone. This study concluded that LDN can control the HFD induced T2DM affected bone abnormalities at multiple hierarchical levels.


Keywords: Bone; Mineralization; Naltrexone; Nano properties; Raman spectroscopy; T2DM.

LDN Protects Bone Property Deterioration at Different Hierarchical Levels in T2DM Mice Bone

 2021 Aug 10. - Type 2 diabetes mellitus (T2DM) commonly affects bone quality at different hierarchical levels and leads to an increase in the risk of bone fracture. Earlier, some anti-diabetic drugs showed positive effects on bone mechanical properties. Recently, we have investigated that low-dose naltrexone (LDN), a TLR4 antagonist treatment, improves glucose tolerance in high-fat diet (HFD)-induced T2DM mice and also gives protection against HFD-induced weight gain. However, effects on bone are still unknown. In this study, the effects of LDN on the bone properties at different hierarchical levels in T2DM mice bone were investigated. In order to investigate these, four different groups of bone (divided based on diet and treatment) were considered in this present study. These are (a) normal control diet treated with saline water, (b) normal control diet treated with LDN, (c) HFD treated with saline water, and (d) HFD treated with LDN. Bone properties were measured in terms of fracture toughness, nano-Young's modulus, hardness, mineral crystal size, bone composition, and bulk mineral to matrix ratio. Results indicated that fracture toughness, nano-Young's modulus, and hardness were decreased in T2DM bone as compared to normal bone, and interestingly, treatment with the LDN increases these material properties in T2DM mice bone. Similarly, as compared to the normal bone, decrease in the mineral crystal size and bulk mineral-to-matrix ratio was observed in the T2DM bone, whereas LDN treatment protects these alterations in the T2DM mice bone. The bone size (bone geometry) was increased in the case of HFD-induced T2DM bone; however, LDN cannot protect to increase the bone size in the T2DM mice bone. 

In conclusion, LDN can be used to control the T2DM-affected bone properties at different hierarchical levels.